

**Vaccination Coverage Statistics for Children in Northern Ireland:  
Completed Primary Immunisations by 12 months**

Quarter*	Year	No. in cohort	***DTaP/IPV/Hib/HepB	MenC	PCV2	PCV1	Rota2	MenB2
Jan-Mar	2011	6066	97.4%	97.3%	97.5%	~	~	~
Apr-June	2011	6089	97.3%	97.2%	97.4%	~	~	~
July-Sept	2011	6515	97.4%	97.4%	97.5%	~	~	~
Oct-Dec	2011	6557	97.5%	97.3%	97.6%	~	~	~
Jan-Mar	2012	6145	97.2%	97.0%	97.1%	~	~	~
Apr-June	2012	6022	97.3%	97.3%	97.5%	~	~	~
July-Sept	2012	6563	97.3%	97.3%	97.4%	~	~	~
Oct-Dec	2012	6253	97.4%	97.3%	97.4%	~	~	~
Jan-Mar	2013	6195	97.4%	97.4%	97.4%	~	~	~
Apr-June	2013	6165	97.7%	97.7%	97.7%	~	~	~
July-Sept	2013	6394	97.4%	96.8%	97.4%	~	~	~
Oct-Dec	2013	6382	97.2%	94.1%	97.2%	~	~	~
Jan-Mar	2014	5784	96.7%	**n/a	96.8%	~	~	~
Apr-June	2014	5869	97.0%	**n/a	96.8%	~	~	~
July-Sept	2014	6431	97.6%	98.6%	97.6%	~	94.3%	~
Oct-Dec	2014	5923	97.9%	98.6%	97.8%	~	94.9%	~
Jan-Mar	2015	5854	97.5%	98.5%	97.5%	~	94.8%	~
Apr-June	2015	5920	97.4%	98.4%	97.3%	~	94.9%	~
July-Sept	2015	6439	97.2%	98.2%	97.1%	~	94.1%	~
Oct-Dec	2015	6104	97.3%	98.2%	97.4%	~	94.3%	~
Jan-Mar	2016	5712	97.1%	98.4%	97.1%	~	94.8%	~
Apr-June	2016	5891	96.7%	97.8%	96.7%	~	94.2%	~
July-Sept	2016	6469	97.1%	97.8%	97.1%	~	94.5%	96.0%
Oct-Dec	2016	6206	96.6%	97.3%	96.7%	~	94.3%	95.7%
Jan-Mar	2017	5752	96.9%	90.4%	97.0%	~	95.1%	96.5%
Apr-June	2017	5981	96.7%	~	96.8%	~	94.8%	96.3%
July-Sept	2017	6312	96.6%	~	96.8%	~	94.5%	96.3%
Oct-Dec	2017	6057	96.3%	~	96.5%	~	93.9%	96.2%
Jan-Mar	2018	5649	95.5%	~	95.8%	~	93.7%	95.4%
Apr-June	2018	5587	95.1%	~	95.4%	~	93.6%	95.2%
July-Sept	2018	6073	94.5%	~	94.9%	~	92.3%	94.7%
Oct-Dec	2018	5844	94.0%	~	94.4%	~	92.2%	94.1%
Jan-Mar	2019	5364	94.2%	~	94.5%	~	91.9%	94.1%
Apr-June	2019	5728	93.8%	~	94.1%	~	91.6%	93.9%
July-Sept	2019	6007	94.0%	~	94.4%	~	91.3%	94.2%
Oct-Dec	2019	5694	95.0%	~	95.3%	~	92.1%	95.0%
Jan-Mar	2020	5411	94.8%	~	95.3%	~	92.6%	95.0%
Apr-June	2020	5505	94.9%	~	95.4%	~	93.0%	95.1%
July-Sept	2020	5954	94.5%	~	94.9%	~	92.5%	94.6%
Oct-Dec	2020	5591	93.7%	~	93.5%	~	91.7%	94.0%
Jan-Mar	2021	5344	94.3%	~	~	96.0%	92.3%	94.4%
Apr-June	2021	5185	93.6%	~	~	95.7%	91.6%	93.9%
July-Sept	2021	5647	93.3%	~	~	95.0%	90.2%	93.6%
Oct-Dec	2021	5352	93.7%	~	~	95.3%	91.1%	94.0%
Jan-Mar	2022	5160	93.2%	~	~	94.9%	91.5%	93.4%
Apr-June	2022	5243	92.0%	~	~	94.2%	90.1%	92.3%
July-Sept	2022	5916	91.2%	~	~	93.8%	88.5%	91.3%
Oct-Dec	2022	5581	92.5%	~	~	94.6%	88.8%	92.8%
Jan-Mar	2023	5092	92.4%	~	~	94.6%	89.7%	92.6%
Apr-June	2023	5046	91.6%	~	~	94.0%	89.4%	91.7%
Jul-Sept	2023	5400	92.5%	~	~	94.6%	89.1%	92.4%
Oct-Dec	2023	5133	92.0%	~	~	94.6%	89.4%	91.9%
Jan-Mar	2024	4838	91.0%	~	~	94.1%	88.6%	91.2%
Apr-June	2024	4821	90.6%	~	~	93.3%	88.0%	90.8%
Jul-Sept	2024	5237	90.6%	~	~	93.2%	87.1%	90.7%
Oct-Dec	2024	5117	91.1%	~	~	93.8%	88.0%	91.4%
Jan-Mar	2025	4807	90.9%	~	~	93.8%	88.5%	91.0%
Apr-June	2025	4826	90.7%	~	~	93.3%	88.4%	90.8%
Jul-Sept	2025	5089	87.9%	~	~	90.9%	85.5%	88.4%

\* children were 12 months old during the quarter

\*\* accurate Men C coverage at 12 months not available (n/a) due to a software change

**\*\*\*DTaP/IPV/Hib/HepB**

**Dip3 =** Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

**Tet3 =** Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

**Pert3 =** Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

**Pol (IPV)3 =** Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

**Hib3 =** *Haemophilus Influenzae* type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

**HepB3 =** Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017) Reporting of vaccine commenced July-September 2018

**MenC =** Meningococcal serogroup C conjugate vaccine was removed from the routine immunisation schedule from 1st July 2016 and children born Jan to Mar 2016 but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017  
~ Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017

**PCV2 =** Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)

**PCV1 =** Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or after the first birthday). This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at one year old (on or after the first birthday)). Jan-Mar 2021 is the first quarter where only PCV1 coverage at 12 months has been evaluated

**Rota2 =** Rotavirus vaccine (2 doses given before 24 weeks of age) (introduced July 2013)

**MenB2 =** Meningococcal serogroup B vaccine (2 doses) (introduced Sept 2015)

**Vaccination Coverage Statistics for Children in BHST:**  
**Completed Primary Immunisations by 12 months**

Quarter*	Year	No. in cohort	***DTaP/IPV/Hib/HepB	MenC	PCV2	PCV1	Rota2	MenB2
Jan-Mar	2011	1076	95.6%	95.4%	95.5%	~	~	~
Apr-June	2011	1149	95.3%	95.0%	95.4%	~	~	~
July-Sept	2011	1223	95.0%	95.1%	95.3%	~	~	~
Oct-Dec	2011	1317	94.8%	94.5%	95.3%	~	~	~
Jan-Mar	2012	1157	95.1%	94.7%	95.3%	~	~	~
Apr-June	2012	1099	95.5%	95.2%	95.4%	~	~	~
July-Sept	2012	1270	96.0%	96.1%	96.1%	~	~	~
Oct-Dec	2012	1216	95.2%	95.0%	95.2%	~	~	~
Jan-Mar	2013	1231	95.0%	95.2%	95.2%	~	~	~
Apr-June	2013	1169	95.2%	95.0%	95.5%	~	~	~
July-Sept	2013	1213	93.7%	93.1%	94.1%	~	~	~
Oct-Dec	2013	1234	94.7%	90.6%	94.7%	~	~	~
Jan-Mar	2014	1117	93.4%	**n/a	93.6%	~	~	~
Apr-June	2014	1120	94.1%	**n/a	93.6%	~	~	~
July-Sept	2014	1263	95.9%	97.7%	96.0%	~	93.0%	~
Oct-Dec	2014	1131	95.2%	97.1%	95.2%	~	92.0%	~
Jan-Mar	2015	1101	95.8%	97.8%	95.8%	~	93.7%	~
Apr-June	2015	1149	95.5%	97.6%	95.3%	~	93.3%	~
July-Sept	2015	1198	94.4%	97.4%	94.2%	~	92.7%	~
Oct-Dec	2015	1151	94.9%	96.5%	95.0%	~	93.0%	~
Jan-Mar	2016	1113	94.6%	97.3%	95.1%	~	94.0%	~
Apr-June	2016	1108	94.0%	95.4%	94.0%	~	92.0%	~
July-Sept	2016	1157	93.9%	95.7%	94.0%	~	92.0%	92.6%
Oct-Dec	2016	1140	93.5%	95.5%	93.5%	~	92.5%	92.7%
Jan-Mar	2017	1062	94.3%	87.8%	94.5%	~	93.9%	94.3%
Apr-June	2017	1103	93.0%	~	93.3%	~	90.6%	92.7%
July-Sept	2017	1187	94.3%	~	94.3%	~	92.8%	93.9%
Oct-Dec	2017	1196	94.1%	~	94.1%	~	92.6%	93.8%
Jan-Mar	2018	1057	92.4%	~	92.7%	~	93.3%	92.2%
Apr-June	2018	990	89.4%	~	89.8%	~	91.0%	89.6%
July-Sept	2018	1083	89.4%	~	90.1%	~	89.3%	89.6%
Oct-Dec	2018	1087	86.6%	~	87.3%	~	86.3%	86.7%
Jan-Mar	2019	1009	88.7%	~	89.3%	~	88.4%	88.6%
Apr-June	2019	1056	86.5%	~	87.2%	~	85.7%	86.9%
July-Sept	2019	1173	87.7%	~	88.7%	~	86.7%	88.5%
Oct-Dec	2019	1066	89.4%	~	90.1%	~	88.5%	90.0%
Jan-Mar	2020	989	90.0%	~	90.4%	~	89.9%	90.4%
Apr-June	2020	1052	90.5%	~	91.1%	~	90.4%	90.8%
July-Sept	2020	1138	89.9%	~	89.9%	~	89.0%	89.6%
Oct-Dec	2020	1061	87.7%	~	87.8%	~	86.6%	88.1%
Jan-Mar	2021	987	89.9%	~	~	92.3%	88.8%	90.0%
Apr-June	2021	985	88.9%	~	~	94.3%	89.5%	89.4%
Jul-Sept	2021	1044	87.9%	~	~	90.4%	85.3%	88.3%
Oct-Dec	2021	998	87.2%	~	~	91.3%	85.6%	88.1%
Jan-Mar	2022	987	85.5%	~	~	90.0%	86.8%	85.8%
Apr-June	2022	927	82.1%	~	~	87.8%	83.2%	83.3%
July-Sept	2022	1099	84.0%	~	~	89.2%	83.4%	84.3%
Oct-Dec	2022	1028	84.9%	~	~	89.4%	82.1%	85.8%
Jan-Mar	2023	878	88.0%	~	~	91.9%	85.3%	88.5%
Apr-June	2023	919	86.0%	~	~	89.9%	84.1%	86.1%
Jul-Sept	2023	1007	86.8%	~	~	90.8%	84.7%	86.9%
Oct-Dec	2023	933	88.9%	~	~	93.0%	86.9%	88.6%
Jan-Mar	2024	895	86.4%	~	~	92.0%	85.9%	86.5%
Apr-June	2024	907	86.3%	~	~	90.0%	84.8%	86.9%
Jul-Sept	2024	928	86.0%	~	~	90.3%	83.6%	85.9%
Oct-Dec	2024	977	86.7%	~	~	90.8%	84.7%	86.6%
Jan-Mar	2025	891	85.1%	~	~	90.5%	85.5%	85.3%
Apr-June	2025	894	85.1%	~	~	90.2%	86.1%	85.8%
Jul-Sept	2025	949	82.4%	~	~	86.4%	82.2%	83.4%

\* children were 12 months old during the quarter

\*\* accurate Men C coverage at 12 months not available (n/a) due to a software change

**\*\*\*DTaP/IPV/Hib/HepB**

Dip3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Tet3 = Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Pert3 = Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Pol (IPV)3 = Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Hib3 = *Haemophilus Influenzae* type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

HepB3 = Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017) Reporting of vaccine commenced July-September 2018

MenC = Meningococcal serogroup C conjugate vaccine was removed from the routine immunisation schedule from 1st July 2016 and children born Jan to Mar 2016 but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017  
~ Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017

PCV2 = Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)

PCV1= Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or after the first birthday). This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at one year old (on or after the first birthday)). Jan-Mar 2021 is the first quarter where only PCV1 coverage at 12 months has been evaluated

Rota2 = Rotavirus vaccine (2 doses given before 24 weeks of age) (introduced July 2013)

MenB2 = Meningococcal serogroup B vaccine (2 doses) (introduced Sept 2015)

Vaccination Coverage Statistics for Children in SEHSCT:  
Completed Primary Immunisations by 12 months

Quarter*	Year	No. in cohort	***DTaP/IPV/Hib/HepB	MenC	PCV2	PCV1	Rota2	MenB2
Jan-Mar	2011	1088	97.0%	97.0%	97.2%	~	~	~
Apr-June	2011	1102	97.2%	96.9%	97.3%	~	~	~
July-Sept	2011	1175	97.7%	97.7%	98.0%	~	~	~
Oct-Dec	2011	1181	97.5%	97.3%	97.5%	~	~	~
Jan-Mar	2012	1077	96.8%	96.8%	96.8%	~	~	~
Apr-June	2012	1114	97.8%	97.8%	97.8%	~	~	~
July-Sept	2012	1235	96.4%	96.3%	96.3%	~	~	~
Oct-Dec	2012	1148	97.1%	97.1%	97.5%	~	~	~
Jan-Mar	2013	1153	97.3%	97.4%	97.7%	~	~	~
Apr-June	2013	1106	98.6%	98.6%	98.6%	~	~	~
July-Sept	2013	1106	97.4%	97.0%	97.5%	~	~	~
Oct-Dec	2013	1148	97.4%	95.0%	97.6%	~	~	~
Jan-Mar	2014	1074	96.3%	**n/a	96.5%	~	~	~
Apr-June	2014	1076	97.8%	**n/a	97.9%	~	~	~
July-Sept	2014	1155	97.9%	99.0%	97.7%	~	93.1%	~
Oct-Dec	2014	1020	97.6%	98.6%	97.7%	~	95.4%	~
Jan-Mar	2015	1054	97.2%	98.3%	97.3%	~	94.2%	~
Apr-June	2015	1050	97.6%	98.5%	97.5%	~	95.0%	~
July-Sept	2015	1188	97.1%	97.9%	97.3%	~	94.5%	~
Oct-Dec	2015	1054	97.2%	98.1%	97.2%	~	93.7%	~
Jan-Mar	2016	1011	97.6%	98.2%	97.5%	~	94.9%	~
Apr-June	2016	1073	96.1%	97.9%	96.3%	~	94.7%	~
July-Sept	2016	1209	97.5%	97.9%	97.4%	~	95.1%	96.8%
Oct-Dec	2016	1093	97.3%	97.8%	97.3%	~	95.2%	96.3%
Jan-Mar	2017	1046	97.3%	90.1%	97.4%	~	94.0%	96.6%
Apr-June	2017	1094	96.3%	~	96.6%	~	94.4%	96.2%
July-Sept	2017	1127	96.6%	~	96.7%	~	94.9%	96.4%
Oct-Dec	2017	1043	96.4%	~	96.4%	~	94.7%	96.2%
Jan-Mar	2018	1022	95.7%	~	96.2%	~	93.9%	96.0%
Apr-June	2018	963	95.5%	~	95.8%	~	93.1%	95.5%
July-Sept	2018	1026	95.1%	~	95.5%	~	91.9%	95.3%
Oct-Dec	2018	1031	95.0%	~	95.1%	~	92.0%	95.0%
Jan-Mar	2019	968	95.1%	~	95.5%	~	91.3%	95.0%
Apr-June	2019	1017	95.6%	~	95.8%	~	92.7%	95.5%
July-Sept	2019	1078	94.2%	~	94.6%	~	91.5%	94.5%
Oct-Dec	2019	1020	96.6%	~	96.7%	~	93.0%	96.2%
Jan-Mar	2020	946	94.8%	~	94.7%	~	92.4%	94.6%
Apr-June	2020	998	94.0%	~	94.3%	~	92.7%	94.1%
July-Sept	2020	1044	94.3%	~	95.0%	~	92.7%	94.9%
Oct-Dec	2020	940	91.8%	~	91.6%	~	90.2%	92.6%
Jan-Mar	2021	950	93.7%	~	~	96.6%	92.7%	94.1%
Apr-June	2021	883	91.3%	~	~	93.7%	88.8%	91.6%
July-Sept	2021	1014	91.4%	~	~	93.4%	88.2%	91.0%
Oct-Dec	2021	903	92.2%	~	~	93.7%	89.9%	92.4%
Jan-Mar	2022	878	92.3%	~	~	93.5%	90.3%	92.5%
Apr-June	2022	941	90.5%	~	~	92.9%	89.8%	90.9%
July-Sept	2022	1035	89.1%	~	~	90.8%	86.8%	89.7%
Oct-Dec	2022	1024	92.1%	~	~	93.4%	87.5%	92.5%
Jan-Mar	2023	934	88.2%	~	~	91.8%	86.3%	88.9%
Apr-June	2023	883	89.1%	~	~	92.8%	87.9%	88.9%
Jul-Sept	2023	973	91.1%	~	~	93.8%	87.8%	90.9%
Oct-Dec	2023	889	90.8%	~	~	93.6%	87.9%	90.6%
Jan-Mar	2024	870	89.0%	~	~	92.0%	87.2%	89.1%
Apr-June	2024	865	88.6%	~	~	91.3%	86.1%	88.4%
Jul-Sept	2024	922	88.4%	~	~	91.4%	85.1%	88.8%
Oct-Dec	2024	934	89.7%	~	~	93.5%	88.0%	90.8%
Jan-Mar	2025	877	90.6%	~	~	94.4%	88.4%	91.1%
Apr-June	2025	894	90.4%	~	~	93.2%	88.3%	90.5%
Jul-Sept	2025	954	87.5%	~	~	90.0%	85.3%	87.8%

\* children were 12 months old during the quarter

\*\* accurate Men C coverage at 12 months not available (n/a) due to a software change

\*\*\*DTaP/IPV/Hib/HepB

Dip3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
Tet3 = Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
Pert3 = Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
Pol (IPV)3 = Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
Hib3 = *Haemophilus Influenzae* type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
HepB3 = Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017) Reporting of vaccine commenced July-September 2018

MenC = Meningococcal serogroup C conjugate vaccine was removed from the routine immunisation schedule from 1st July 2016 and children born Jan to Mar 2016 but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017  
~ Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017

PCV2 = Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)

PCV1= Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or after the first birthday). This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at one year old (on or after the first birthday)). Jan-Mar 2021 is the first quarter where only PCV1 coverage at 12 months has been evaluated  
Rota2 = Rotavirus vaccine (2 doses given before 24 weeks of age) (introduced July 2013)  
MenB2 = Meningococcal serogroup B vaccine (2 doses) (introduced Sept 2015)

Vaccination Coverage Statistics for Children in NHSCT:  
Completed Primary Immunisations by 12 months

Quarter*	Year	No. in cohort	***DTaP/IPV/Hib/HepB	MenC	PCV2	PCV1	Rota2	MenB2
Jan-Mar	2011	1442	97.9%	97.7%	97.9%	~	~	~
Apr-June	2011	1466	97.9%	97.9%	98.0%	~	~	~
July-Sept	2011	1562	97.3%	97.3%	97.2%	~	~	~
Oct-Dec	2011	1554	98.1%	97.9%	98.3%	~	~	~
Jan-Mar	2012	1483	97.6%	97.4%	97.4%	~	~	~
Apr-June	2012	1476	96.8%	96.7%	97.0%	~	~	~
July-Sept	2012	1535	97.5%	97.1%	97.5%	~	~	~
Oct-Dec	2012	1458	97.9%	97.9%	98.0%	~	~	~
Jan-Mar	2013	1446	97.6%	97.4%	97.5%	~	~	~
Apr-June	2013	1448	97.3%	97.2%	97.2%	~	~	~
July-Sept	2013	1536	98.1%	97.1%	97.9%	~	~	~
Oct-Dec	2013	1521	97.6%	94.3%	97.6%	~	~	~
Jan-Mar	2014	1395	97.6%	**n/a	97.6%	~	~	~
Apr-June	2014	1432	96.2%	**n/a	96.2%	~	~	~
July-Sept	2014	1538	97.7%	98.8%	97.6%	~	95.7%	~
Oct-Dec	2014	1432	98.5%	98.8%	98.3%	~	94.8%	~
Jan-Mar	2015	1416	97.7%	98.8%	97.7%	~	95.1%	~
Apr-June	2015	1388	97.9%	98.8%	98.0%	~	95.9%	~
July-Sept	2015	1547	97.6%	98.1%	97.4%	~	94.1%	~
Oct-Dec	2015	1504	98.4%	98.9%	98.3%	~	94.9%	~
Jan-Mar	2016	1374	97.5%	98.4%	97.5%	~	95.0%	~
Apr-June	2016	1425	97.9%	98.9%	98.0%	~	95.1%	~
July-Sept	2016	1523	98.2%	98.8%	98.2%	~	95.3%	97.2%
Oct-Dec	2016	1486	97.2%	97.7%	97.2%	~	94.7%	95.9%
Jan-Mar	2017	1323	97.6%	90.6%	97.5%	~	96.1%	97.0%
Apr-June	2017	1426	97.4%	~	97.4%	~	96.1%	97.0%
July-Sept	2017	1488	96.8%	~	97.1%	~	95.4%	96.6%
Oct-Dec	2017	1472	96.9%	~	97.1%	~	95.0%	96.7%
Jan-Mar	2018	1364	96.0%	~	96.2%	~	93.8%	95.8%
Apr-June	2018	1326	95.6%	~	96.3%	~	93.7%	96.2%
July-Sept	2018	1496	95.3%	~	95.7%	~	92.6%	95.5%
Oct-Dec	2018	1400	96.3%	~	96.6%	~	94.4%	96.4%
Jan-Mar	2019	1228	95.4%	~	95.4%	~	92.8%	95.2%
Apr-June	2019	1361	95.3%	~	95.5%	~	94.1%	95.3%
July-Sept	2019	1381	95.7%	~	95.9%	~	93.3%	95.5%
Oct-Dec	2019	1340	96.6%	~	97.1%	~	93.8%	96.9%
Jan-Mar	2020	1302	96.5%	~	96.7%	~	94.0%	96.3%
Apr-June	2020	1302	97.2%	~	97.6%	~	95.7%	97.5%
July-Sept	2020	1418	95.8%	~	96.1%	~	94.1%	96.0%
Oct-Dec	2020	1359	95.6%	~	95.5%	~	94.6%	95.7%
Jan-Mar	2021	1257	96.2%	~	~	96.7%	92.9%	96.1%
Apr-June	2021	1283	95.6%	~	~	96.8%	93.4%	95.8%
July-Sept	2021	1382	95.6%	~	~	97.0%	92.8%	95.9%
Oct-Dec	2021	1268	97.8%	~	~	98.3%	94.9%	97.8%
Jan-Mar	2022	1209	95.8%	~	~	96.6%	93.5%	96.0%
Apr-June	2022	1282	95.8%	~	~	97.6%	93.5%	95.9%
July-Sept	2022	1368	94.1%	~	~	96.3%	91.3%	93.6%
Oct-Dec	2022	1313	94.6%	~	~	95.7%	90.9%	94.4%
Jan-Mar	2023	1234	94.9%	~	~	96.7%	92.0%	94.9%
Apr-June	2023	1222	93.9%	~	~	95.6%	91.8%	94.1%
Jul-Sept	2023	1324	94.6%	~	~	96.1%	91.4%	94.5%
Oct-Dec	2023	1265	94.3%	~	~	96.4%	92.2%	94.3%
Jan-Mar	2024	1140	92.5%	~	~	95.2%	90.5%	92.8%
Apr-June	2024	1183	93.5%	~	~	95.1%	90.4%	93.0%
Jul-Sept	2024	1299	92.9%	~	~	94.5%	88.8%	92.8%
Oct-Dec	2024	1203	94.0%	~	~	96.2%	91.9%	94.3%
Jan-Mar	2025	1116	93.5%	~	~	95.0%	90.4%	93.5%
Apr-June	2025	1181	93.8%	~	~	95.3%	90.6%	93.1%
Jul-Sept	2025	1193	89.1%	~	~	92.4%	87.0%	89.4%

\* children were 12 months old during the quarter

\*\* accurate Men C coverage at 12 months not available (n/a) due to a software change

\*\*\*DTaP/IPV/Hib/HepB

Dip3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
Tet3 = Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
Pert3 = Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
Pol (IPV)3 = Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
Hib3 = *Haemophilus Influenzae* type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
HepB3 = Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017) Reporting of vaccine commenced July-September 2018

MenC = Meningococcal serogroup C conjugate vaccine was removed from the routine immunisation schedule from 1st July 2016 and children born Jan to Mar 2016 but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017  
~ Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017  
PCV2 = Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)  
PCV1= Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or after the first birthday). This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at one year old (on or after the first birthday)). Jan-Mar 2021 is the first quarter where only PCV1 coverage at 12 months has been evaluated  
Rota2 = Rotavirus vaccine (2 doses given before 24 weeks of age) (introduced July 2013)  
MenB2 = Meningococcal serogroup B vaccine (2 doses) (introduced Sept 2015)

Vaccination Coverage Statistics for Children in SHSCT:  
Completed Primary Immunisations by 12 months

Quarter*	Year	No. in cohort	***DTaP/IPV/Hib/HepB	MenC	PCV2	PCV1	Rota2	MenB2
Jan-Mar	2011	1404	98.0%	97.9%	98.1%			
Apr-June	2011	1345	97.8%	97.6%	97.7%			
July-Sept	2011	1479	98.0%	97.7%	97.8%			
Oct-Dec	2011	1440	98.5%	98.4%	98.3%			
Jan-Mar	2012	1373	97.9%	97.7%	97.7%			
Apr-June	2012	1282	98.1%	98.0%	98.4%			
July-Sept	2012	1440	98.1%	98.1%	98.2%			
Oct-Dec	2012	1371	98.0%	97.8%	97.8%			
Jan-Mar	2013	1344	98.6%	98.6%	98.6%			
Apr-June	2013	1412	98.5%	98.6%	98.5%			
July-Sept	2013	1520	98.6%	98.0%	98.4%			
Oct-Dec	2013	1411	98.2%	96.0%	98.0%			
Jan-Mar	2014	1297	98.5%	**n/a	98.2%			
Apr-June	2014	1322	98.4%	**n/a	98.3%			
July-Sept	2014	1411	98.4%	98.7%	98.4%		95.6%	
Oct-Dec	2014	1356	99.0%	99.4%	99.0%		96.3%	
Jan-Mar	2015	1341	98.4%	99.0%	98.2%		96.2%	
Apr-June	2015	1367	98.4%	98.5%	98.0%		95.2%	
July-Sept	2015	1407	98.5%	98.8%	98.4%		95.0%	
Oct-Dec	2015	1394	97.8%	98.5%	97.9%		95.1%	
Jan-Mar	2016	1306	97.8%	99.1%	97.7%		95.9%	
Apr-June	2016	1309	97.4%	98.2%	97.2%		95.3%	
July-Sept	2016	1482	97.6%	98.0%	97.4%		94.7%	96.3%
Oct-Dec	2016	1442	97.4%	97.4%	97.6%		94.9%	97.0%
Jan-Mar	2017	1357	97.7%	90.9%	97.6%		95.5%	97.1%
Apr-June	2017	1373	98.6%	~	98.6%		96.9%	98.3%
July-Sept	2017	1450	97.4%	~	97.4%		95.4%	96.8%
Oct-Dec	2017	1371	97.2%	~	97.5%		93.9%	97.0%
Jan-Mar	2018	1257	96.0%	~	96.4%		94.0%	95.9%
Apr-June	2018	1360	97.4%	~	97.4%		95.1%	97.0%
July-Sept	2018	1463	96.9%	~	97.0%		94.8%	96.9%
Oct-Dec	2018	1306	96.0%	~	96.2%		94.0%	96.0%
Jan-Mar	2019	1237	96.4%	~	96.6%		93.9%	96.4%
Apr-June	2019	1324	95.4%	~	95.5%		93.6%	95.4%
July-Sept	2019	1399	95.4%	~	95.6%		92.8%	95.4%
Oct-Dec	2019	1341	96.0%	~	96.0%		93.9%	95.6%
Jan-Mar	2020	1241	96.2%	~	96.9%		93.9%	96.5%
Apr-June	2020	1276	96.0%	~	96.5%		94.5%	96.0%
July-Sept	2020	1399	95.9%	~	96.5%		93.3%	96.5%
Oct-Dec	2020	1317	96.1%	~	95.7%		93.3%	96.4%
Jan-Mar	2021	1239	95.4%	~	~	96.8%	93.6%	95.5%
Apr-June	2021	1155	95.2%	~	~	96.1%	92.6%	95.1%
July-Sept	2021	1302	95.1%	~	~	96.6%	92.5%	95.7%
Oct-Dec	2021	1223	94.9%	~	~	96.0%	92.2%	95.2%
Jan-Mar	2022	1194	95.6%	~	~	96.6%	93.9%	95.3%
Apr-June	2022	1209	93.5%	~	~	94.6%	90.3%	93.6%
July-Sept	2022	1408	93.1%	~	~	95.5%	89.3%	93.0%
Oct-Dec	2022	1296	94.8%	~	~	97.1%	92.1%	94.8%
Jan-Mar	2023	1211	94.7%	~	~	95.6%	92.1%	95.0%
Apr-June	2023	1194	94.1%	~	~	95.6%	91.5%	94.1%
Jul-Sept	2023	1241	93.6%	~	~	95.2%	90.9%	93.2%
Oct-Dec	2023	1183	92.5%	~	~	94.4%	89.8%	92.3%
Jan-Mar	2024	1124	93.4%	~	~	95.2%	90.8%	93.3%
Apr-June	2024	1091	91.5%	~	~	94.5%	89.5%	91.8%
Jul-Sept	2024	1241	92.3%	~	~	94.5%	89.0%	92.3%
Oct-Dec	2024	1191	92.0%	~	~	94.0%	88.7%	91.9%
Jan-Mar	2025	1096	91.6%	~	~	93.7%	89.9%	91.3%
Apr-June	2025	1053	92.2%	~	~	93.9%	89.4%	92.3%
Jul-Sept	2025	1182	90.8%	~	~	92.8%	87.6%	91.0%

\* children were 12 months old during the quarter

\*\* accurate Men C coverage at 12 months not available (n/a) due to a software change

\*\*\*DTaP/IPV/Hib/HepB

Dip3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
Tet3 = Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
Pert3 = Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
Pol (IPV)3 = Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
Hib3 = *Haemophilus Influenzae* type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
HepB3 = Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017) Reporting of vaccine commenced July-September 2018

MenC = Meningococcal serogroup C conjugate vaccine was removed from the routine immunisation schedule from 1st July 2016 and children born Jan to Mar 2016 but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017  
~ Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017  
PCV2 = Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)  
PCV1= Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or after the first birthday). This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at one year old (on or after the first birthday)). Jan-Mar 2021 is the first quarter where only PCV1 coverage at 12 months has been evaluated  
Rota2 = Rotavirus vaccine (2 doses given before 24 weeks of age) (introduced July 2013)  
MenB2 = Meningococcal serogroup B vaccine (2 doses) (introduced Sept 2015)

Vaccination Coverage Statistics for Children in WHSCT:  
Completed Primary Immunisations by 12 months

Quarter*	Year	No. in cohort	***DTaP/IPV/Hib/HepB	MenC	PCV2	PCV1	Rota2	MenB2
Jan-Mar	2011	1056	98.2%	98.1%	98.3%	~	~	~
Apr-June	2011	1027	98.3%	98.2%	98.3%	~	~	~
July-Sept	2011	1076	99.3%	99.3%	99.3%	~	~	~
Oct-Dec	2011	1065	98.4%	98.4%	98.3%	~	~	~
Jan-Mar	2012	1055	98.3%	98.3%	98.3%	~	~	~
Apr-June	2012	1051	98.7%	98.7%	98.7%	~	~	~
July-Sept	2012	1083	98.8%	99.0%	98.8%	~	~	~
Oct-Dec	2012	1060	98.6%	98.6%	98.6%	~	~	~
Jan-Mar	2013	1021	98.3%	98.1%	98.1%	~	~	~
Apr-June	2013	1030	98.9%	99.0%	98.9%	~	~	~
July-Sept	2013	1019	98.9%	98.7%	98.9%	~	~	~
Oct-Dec	2013	1068	97.9%	94.5%	97.9%	~	~	~
Jan-Mar	2014	901	97.8%	**n/a	97.8%	~	~	~
Apr-June	2014	919	98.6%	**n/a	98.6%	~	~	~
July-Sept	2014	1064	98.3%	98.7%	98.3%	~	93.6%	~
Oct-Dec	2014	984	98.6%	99.2%	98.5%	~	96.1%	~
Jan-Mar	2015	942	97.9%	98.7%	98.1%	~	94.6%	~
Apr-June	2015	966	97.5%	98.9%	97.6%	~	94.5%	~
July-Sept	2015	1099	97.9%	98.9%	97.9%	~	94.4%	~
Oct-Dec	2015	1001	98.0%	98.8%	98.1%	~	94.3%	~
Jan-Mar	2016	908	98.0%	99.1%	98.0%	~	94.1%	~
Apr-June	2016	976	97.6%	98.0%	97.4%	~	93.1%	~
July-Sept	2016	1098	98.2%	98.5%	98.0%	~	94.9%	96.4%
Oct-Dec	2016	1045	97.3%	97.9%	97.4%	~	93.8%	96.3%
Jan-Mar	2017	964	97.3%	92.6%	97.8%	~	95.4%	97.3%
Apr-June	2017	985	97.6%	~	97.4%	~	95.1%	96.5%
July-Sept	2017	1060	98.0%	~	98.3%	~	93.2%	97.7%
Oct-Dec	2017	975	96.7%	~	97.3%	~	93.2%	97.3%
Jan-Mar	2018	949	97.0%	~	97.2%	~	93.2%	96.9%
Apr-June	2018	948	96.6%	~	96.6%	~	94.1%	96.6%
July-Sept	2018	1005	94.9%	~	95.3%	~	91.6%	95.2%
Oct-Dec	2018	1020	95.4%	~	95.9%	~	93.0%	95.9%
Jan-Mar	2019	922	94.8%	~	95.2%	~	92.2%	94.5%
Apr-June	2019	970	95.9%	~	96.1%	~	90.3%	95.7%
July-Sept	2019	976	97.0%	~	97.4%	~	91.7%	97.3%
Oct-Dec	2019	927	95.8%	~	96.5%	~	90.5%	96.0%
Jan-Mar	2020	933	95.7%	~	96.8%	~	92.2%	96.6%
Apr-June	2020	877	96.4%	~	96.9%	~	90.5%	96.8%
July-Sept	2020	955	96.1%	~	96.4%	~	92.9%	95.6%
Oct-Dec	2020	915	96.1%	~	95.7%	~	92.6%	96.4%
Jan-Mar	2021	911	95.7%	~	~	97.5%	93.2%	95.6%
Apr-June	2021	879	96.1%	~	~	97.3%	92.7%	97.0%
July-Sept	2021	905	95.4%	~	~	96.4%	90.9%	95.8%
Oct-Dec	2021	960	95.0%	~	~	96.0%	91.8%	95.0%
Jan-Mar	2022	892	95.9%	~	~	97.1%	91.7%	96.7%
Apr-June	2022	884	96.2%	~	~	97.1%	92.5%	96.0%
July-Sept	2022	1006	94.7%	~	~	96.3%	90.7%	94.9%
Oct-Dec	2022	920	95.2%	~	~	96.6%	90.2%	95.8%
Jan-Mar	2023	835	94.9%	~	~	96.2%	91.0%	94.5%
Apr-June	2023	828	93.4%	~	~	95.3%	90.3%	93.8%
Jul-Sept	2023	855	95.8%	~	~	97.1%	89.6%	96.1%
Oct-Dec	2023	863	92.8%	~	~	94.9%	89.0%	92.8%
Jan-Mar	2024	809	92.6%	~	~	95.7%	87.3%	93.4%
Apr-June	2024	775	92.1%	~	~	94.7%	88.3%	93.0%
Jul-Sept	2024	847	92.2%	~	~	94.3%	87.5%	92.3%
Oct-Dec	2024	812	92.2%	~	~	93.7%	85.1%	92.9%
Jan-Mar	2025	827	92.9%	~	~	95.4%	87.2%	93.3%
Apr-June	2025	804	90.7%	~	~	93.2%	86.8%	91.4%
Jul-Sept	2025	811	89.0%	~	~	92.4%	84.3%	89.8%

\* children were 12 months old during the quarter

\*\* accurate Men C coverage at 12 months not available (n/a) due to a software change

\*\*\*DTaP/IPV/Hib/HepB

Dip3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
Tet3 = Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
Pert3 = Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
Pol (IPV)3 = Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
Hib3 = *Haemophilus Influenzae* type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017  
HepB3 = Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017) Reporting of vaccine commenced July-September 2018

MenC = Meningococcal serogroup C conjugate vaccine was removed from the routine immunisation schedule from 1st July 2016 and children born Jan to Mar 2016 but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017  
~ Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017  
PCV2 = Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)  
PCV1= Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or after the first birthday).  
This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at one year old (on or after the first birthday)).  
Jan-Mar 2021 is the first quarter where only PCV1 coverage at 12 months has been evaluated  
Rota2 = Rotavirus vaccine (2 doses given before 24 weeks of age) (introduced July 2013)  
MenB2 = Meningococcal serogroup B vaccine (2 doses) (introduced Sept 2015)